Cargando…
Metabolic features of orbital adipose tissue in patients with thyroid eye disease
BACKGROUND: Thyroid eye disease (TED) is the most frequent orbital disease in adults and is characterized by the accumulation of orbital adipose tissue (OAT). It can lead to eyelid retraction or even vision loss. Orbital decompression surgery serves as the primary treatment for inactive TED by remov...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435847/ https://www.ncbi.nlm.nih.gov/pubmed/37600696 http://dx.doi.org/10.3389/fendo.2023.1151757 |
_version_ | 1785092196378083328 |
---|---|
author | Du, Rui Wang, Fenfen Yang, Chun Hu, Jing Liu, Jiapei Jian, Qizhi Wang, Ruonan Zhang, Jian Chen, Hui Wang, Yufan Zhang, Fang |
author_facet | Du, Rui Wang, Fenfen Yang, Chun Hu, Jing Liu, Jiapei Jian, Qizhi Wang, Ruonan Zhang, Jian Chen, Hui Wang, Yufan Zhang, Fang |
author_sort | Du, Rui |
collection | PubMed |
description | BACKGROUND: Thyroid eye disease (TED) is the most frequent orbital disease in adults and is characterized by the accumulation of orbital adipose tissue (OAT). It can lead to eyelid retraction or even vision loss. Orbital decompression surgery serves as the primary treatment for inactive TED by removing the excess OAT. However, there is a lack of alternative treatments to surgery due to the unclear understanding of the pathogenesis, particularly the metabolic features. Accordingly, our study was implemented to explore the content and features of metabolites of OATs from TED patients. METHOD: The OATs used in the current study were obtained from the orbital decompression surgery of seven patients with inactive TED. We also collected control OATs from eye surgical samples of five individuals with no history of autoimmune thyroid diseases, TED, or under non-inflammatory conditions. The liquid chromatography mass spectrometer was used for the measurements of the targeted metabolites. Afterwards, we performed differential metabolite assay analysis and related pathway enrichment analysis. RESULTS: In our study, a total of 149 metabolite profiles were detected in all participants. There were significant differences in several metabolite profiles between the TED group and the control group, mainly including uric acid, oxidized glutathione, taurine, dGMP, oxidized glutathione 2, uracil, hexose-phosphate, 1-methylnicotinamide, D-sedoheptulose 1,7-bisphosphate, and uridine 5′-monophosphate (all p-value < 0.05). The TED-related pathways identified included purine metabolism, beta-alanine metabolism, glutathione metabolism (p-values < 0.05). Our study found overlaps and differences including uric acid and uracil, which are in accordance with metabolites found in blood of patients with TED from previous study and several newly discovered metabolite by our study such as hexose-phosphate, 1-methylnicotinamide, D-sedoheptulose 1,7-bisphosphate, compared to those tested from blood, OAT, or urine samples reported in previous studies. CONCLUSION: The findings of our study shed light on the metabolic features of OAT in individuals with TED. These results may help identify new treatment targets for TED, providing potential avenues for developing alternative treatments beyond ophthalmic surgery. |
format | Online Article Text |
id | pubmed-10435847 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104358472023-08-19 Metabolic features of orbital adipose tissue in patients with thyroid eye disease Du, Rui Wang, Fenfen Yang, Chun Hu, Jing Liu, Jiapei Jian, Qizhi Wang, Ruonan Zhang, Jian Chen, Hui Wang, Yufan Zhang, Fang Front Endocrinol (Lausanne) Endocrinology BACKGROUND: Thyroid eye disease (TED) is the most frequent orbital disease in adults and is characterized by the accumulation of orbital adipose tissue (OAT). It can lead to eyelid retraction or even vision loss. Orbital decompression surgery serves as the primary treatment for inactive TED by removing the excess OAT. However, there is a lack of alternative treatments to surgery due to the unclear understanding of the pathogenesis, particularly the metabolic features. Accordingly, our study was implemented to explore the content and features of metabolites of OATs from TED patients. METHOD: The OATs used in the current study were obtained from the orbital decompression surgery of seven patients with inactive TED. We also collected control OATs from eye surgical samples of five individuals with no history of autoimmune thyroid diseases, TED, or under non-inflammatory conditions. The liquid chromatography mass spectrometer was used for the measurements of the targeted metabolites. Afterwards, we performed differential metabolite assay analysis and related pathway enrichment analysis. RESULTS: In our study, a total of 149 metabolite profiles were detected in all participants. There were significant differences in several metabolite profiles between the TED group and the control group, mainly including uric acid, oxidized glutathione, taurine, dGMP, oxidized glutathione 2, uracil, hexose-phosphate, 1-methylnicotinamide, D-sedoheptulose 1,7-bisphosphate, and uridine 5′-monophosphate (all p-value < 0.05). The TED-related pathways identified included purine metabolism, beta-alanine metabolism, glutathione metabolism (p-values < 0.05). Our study found overlaps and differences including uric acid and uracil, which are in accordance with metabolites found in blood of patients with TED from previous study and several newly discovered metabolite by our study such as hexose-phosphate, 1-methylnicotinamide, D-sedoheptulose 1,7-bisphosphate, compared to those tested from blood, OAT, or urine samples reported in previous studies. CONCLUSION: The findings of our study shed light on the metabolic features of OAT in individuals with TED. These results may help identify new treatment targets for TED, providing potential avenues for developing alternative treatments beyond ophthalmic surgery. Frontiers Media S.A. 2023-08-03 /pmc/articles/PMC10435847/ /pubmed/37600696 http://dx.doi.org/10.3389/fendo.2023.1151757 Text en Copyright © 2023 Du, Wang, Yang, Hu, Liu, Jian, Wang, Zhang, Chen, Wang and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Du, Rui Wang, Fenfen Yang, Chun Hu, Jing Liu, Jiapei Jian, Qizhi Wang, Ruonan Zhang, Jian Chen, Hui Wang, Yufan Zhang, Fang Metabolic features of orbital adipose tissue in patients with thyroid eye disease |
title | Metabolic features of orbital adipose tissue in patients with thyroid eye disease |
title_full | Metabolic features of orbital adipose tissue in patients with thyroid eye disease |
title_fullStr | Metabolic features of orbital adipose tissue in patients with thyroid eye disease |
title_full_unstemmed | Metabolic features of orbital adipose tissue in patients with thyroid eye disease |
title_short | Metabolic features of orbital adipose tissue in patients with thyroid eye disease |
title_sort | metabolic features of orbital adipose tissue in patients with thyroid eye disease |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435847/ https://www.ncbi.nlm.nih.gov/pubmed/37600696 http://dx.doi.org/10.3389/fendo.2023.1151757 |
work_keys_str_mv | AT durui metabolicfeaturesoforbitaladiposetissueinpatientswiththyroideyedisease AT wangfenfen metabolicfeaturesoforbitaladiposetissueinpatientswiththyroideyedisease AT yangchun metabolicfeaturesoforbitaladiposetissueinpatientswiththyroideyedisease AT hujing metabolicfeaturesoforbitaladiposetissueinpatientswiththyroideyedisease AT liujiapei metabolicfeaturesoforbitaladiposetissueinpatientswiththyroideyedisease AT jianqizhi metabolicfeaturesoforbitaladiposetissueinpatientswiththyroideyedisease AT wangruonan metabolicfeaturesoforbitaladiposetissueinpatientswiththyroideyedisease AT zhangjian metabolicfeaturesoforbitaladiposetissueinpatientswiththyroideyedisease AT chenhui metabolicfeaturesoforbitaladiposetissueinpatientswiththyroideyedisease AT wangyufan metabolicfeaturesoforbitaladiposetissueinpatientswiththyroideyedisease AT zhangfang metabolicfeaturesoforbitaladiposetissueinpatientswiththyroideyedisease |